Treatment of autosomal dominant hearing loss by in vivo delivery of genome editing agents

Journal: Nature

Published: 2017-12-20

DOI: 10.1038/nature25164

Affiliations: 14

Authors: 20

Go to article
Institutions FC
Harvard Division of Medical Sciences (DMS), United States of America (USA) 0.19
Harvard Eaton-Peabody Laboratories (EPL), MEEI, United States of America (USA) 0.19
Tufts Department of Biomedical Engineering, United States of America (USA) 0.10
Harvard Department of Chemistry and Chemical Biology (CCB), United States of America (USA) 0.09
Harvard University, United States of America (USA) 0.09
Wuhan Union Hospital, HUST, China 0.08
MOE Key Laboratory of Hearing Impairment Science, PLAGH, China 0.07
Broad Institute of MIT and Harvard, United States of America (USA) 0.06
Harvard Medical School (HMS), United States of America (USA) 0.03
Department of Otolaryngology and Communication Enhancement, BCH, United States of America (USA) 0.03
Department of Neurology, BCH, United States of America (USA) 0.03
F.M. Kirby Neurobiology Center, BCH, United States of America (USA) 0.03
Department of Otolaryngology at Head and Neck Surgery, Eye and ENT Hospital, Fudan University, China 0.02
Harvard-MIT Program in Speech and Hearing Bioscience and Technology (SHBT), United States of America (USA) 0.01

Return